Adaptive crossover designs for assessment of symptomatic treatments targeting behaviour in neurodegenerative disease: a phase 2 clinical trial of intranasal oxytocin for frontotemporal dementia (FOXY)

BACKGROUND: There are currently no treatments for empathy deficits in neuropsychiatric disorders. Acute administration of the hormone oxytocin has been associated with symptomatic improvements across animal models and several neuropsychiatric disorders, but results of the majority of oxytocin random...

Descripción completa

Detalles Bibliográficos
Autores principales: Finger, Elizabeth, Berry, Scott, Cummings, Jeffrey, Coleman, Kristy, Hsiung, Robin, Feldman, Howard H., Boxer, Adam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6161323/
https://www.ncbi.nlm.nih.gov/pubmed/30261917
http://dx.doi.org/10.1186/s13195-018-0427-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6161323/
https://www.ncbi.nlm.nih.gov/pubmed/30261917
http://dx.doi.org/10.1186/s13195-018-0427-2

Ejemplares similares